This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hengstler, J. G. Articles by Tanner, B. Search for Related Content PubMed PubMed Citation Articles by Hengstler, J. G. Articles by Tanner, B.

Contribution of c-erbB-2 and Topoisomerase II to Chemoresistance in Ovarian Cancer¹

Institute of Toxicology [J. G. H., J. L., N. D., M. A., R. B., F. O.], Department of Gynecology [A. K., P. G. K., B. T.], and Institute of Statistics and Documentation [R. M.], University of Mainz, 55131 Mainz, Germany

Overexpression of the c-erbB-2 (HER-2/neu) oncogene, which encodes a transmembrane receptor tyrosine kinase, has been shown to be associated with poor prognosis in ovarian and breast cancer. Recent studies indicate that c-erbB-2 may also be involved in determining the chemosensitivity of human cancers. In the present study, we examined the role of c-erbB-2 for chemoresistance in ovarian cancer. Overexpression of c-erbB-2 mRNA in tumor tissue was associated with a shorter survival of patients with primary ovarian cancer (P = 0.0001; n = 77) and was an independent prognostic factor in the proportional-hazard model adjusted for International Federation of Gynecologists and Obstetricians stage, residual disease, chemotherapy, and age (P = 0.035). A significant association between expression of c-erbB-2 mRNA and survival was obtained for the subgroup of patients who received a standard chemotherapy with carboplatin or cisplatin and cyclophosphamide (P = 0.0003), whereas only a nonsignificant trend was observed for patients who did not receive a standard chemotherapy (P = 0.124). In addition, the application of a standard chemotherapy improved the survival of patients with relatively low c-erbB-2 expression (P = 0.013) but not of patients with overexpression of c-erbB-2 (P = 0.359). Expression of c-erbB-2 mRNA correlated with expression of topoisomerase II mRNA determined by a reverse semiquantitative PCR technique (P = 0.009), whereas expression of c-erbB-2 and topoisomerase IIß mRNA did not correlate (P = 0.221). To examine the hypothesis that coamplified and/or coregulated topoisomerase II contributes to the resistance of c-erbB-2-overexpressing carcinomas, we established a chemosensitivity assay using primary cells from an ovarian carcinoma that overexpressed both c-erbB-2 and topoisomerase II. The combination of carboplatin with nontoxic concentrations of the topoisomerase II inhibitors etoposide or novobiocin enhanced the toxicity of carboplatin. In contrast, the tyrosine kinase inhibitor emodin exhibited no chemosensitizing effect in cells of this individual carcinoma. In conclusion, overexpression of c-erbB-2 was associated with poor prognosis and poor response to chemotherapy. The data suggest that topoisomerase II, which correlates with c-erbB-2 expression, contributes to the resistance of c-erbB-2-overexpressing carcinomas.

This article has been cited by other articles:

				B. Tanner, D. Hasenclever, K. Stern, W. Schormann, M. Bezler, M. Hermes, M. Brulport, A. Bauer, I. B. Schiffer, S. Gebhard, et al. ErbB-3 Predicts Survival in Ovarian Cancer J. Clin. Oncol., September 10, 2006; 24(26): 4317 - 4323. [Abstract] [Full Text] [PDF]

				C. Spangenberg, E. U. Lausch, T. M. Trost, D. Prawitt, A. May, R. Keppler, S. A. Fees, D. Reutzel, C. Bell, S. Schmitt, et al. ERBB2-Mediated Transcriptional Up-regulation of the {alpha}5{beta}1 Integrin Fibronectin Receptor Promotes Tumor Cell Survival Under Adverse Conditions. Cancer Res., April 1, 2006; 66(7): 3715 - 3725. [Abstract] [Full Text] [PDF]

				M. Komatsu, K. Hiyama, K. Tanimoto, M. Yunokawa, K. Otani, M. Ohtaki, E. Hiyama, J. Kigawa, M. Ohwada, M. Suzuki, et al. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol. Cancer Ther., March 1, 2006; 5(3): 767 - 775. [Abstract] [Full Text] [PDF]

				S. Camilleri-Broet, A. C. Hardy-Bessard, A. Le Tourneau, D. Paraiso, O. Levrel, B. Leduc, S. Bain, H. Orfeuvre, J. Audouin, and E. Pujade-Lauraine HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group Ann. Onc., January 1, 2004; 15(1): 104 - 112. [Abstract] [Full Text] [PDF]

				I. B. Schiffer, S. Gebhard, C. K. Heimerdinger, A. Heling, J. Hast, U. Wollscheid, B. Seliger, B. Tanner, S. Gilbert, T. Beckers, et al. Switching Off HER-2/neu in a Tetracycline-Controlled Mouse Tumor Model Leads to Apoptosis and Tumor-Size-Dependent Remission Cancer Res., November 1, 2003; 63(21): 7221 - 7231. [Abstract] [Full Text] [PDF]

				P. Micke, M. Basrai, A. Faldum, F. Bittinger, L. Ronnstrand, A. Blaukat, K. M. Beeh, F. Oesch, B. Fischer, R. Buhl, et al. Characterization of c-kit Expression in Small Cell Lung Cancer: Prognostic and Therapeutic Implications Clin. Cancer Res., January 1, 2003; 9(1): 188 - 194. [Abstract] [Full Text] [PDF]